Načítá se...
Early treatment uptake and cost burden of hepatitis C therapies among newly diagnosed hepatitis C patients with a particular focus on HIV coinfection
BACKGROUND: Despite the high efficacy and safety associated with direct-acting antivirals (DAAs), access to HCV treatment has been frequently restricted because of the high DAA drug costs. OBJECTIVES: To (1) compare HCV treatment initiation rates between HCV monoinfected and HCV/HIV coinfected patie...
Uloženo v:
| Vydáno v: | Dig Dis Sci |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7358122/ https://ncbi.nlm.nih.gov/pubmed/31938995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-019-06037-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|